### **Luncheon Symposium 3** SSBH 2025 I [Yuyu Pharma]

12:40-12:55 | Room 1

# **Hyo-Jeong Kim**

Professor

Department of Internal Medicine, Nowon Eulji University Hospital, Eulji University, Korea

## Educational Background & Professional Experience

2016.3-Present	Professor, Department of Internal Medicine, Eulji University
2014.8-2015.7	Visiting scientist, Department of Internal Medicine, Harvard University
2009.9-2016.2	Associate Professor, Department of Internal Medicine, Eulji University
2005.9-2009.8	Assistant Professor, Department of Internal Medicine, Eulji University
2002.4-2004.2	Postdoctoral fellow, Department of Internal Medicine, Yale University
2000.3-2002.2	Fellow, Department of Internal Medicine, Ajou University Hospital
1996.3-2000.2	Resident, Department of Internal Medicine, Ewha University Hospital

#### Research Interests

Osteoporosis, Endocrinology and Metabolism

## Publications

- 1. Ha JH, Jung KY, Ahn SH, Kim H–J, Chung Y–S 7; MAXCARE Research Group. Effects of Sequential Anti–Resorptive Agents on Bone Mineral Density Following Denosumab Withdrawal: A Multicenter Real-World Study in Korea (MAXCARE Study). 2025 Feb 11. doi:10.3803/EnM.2024.2227
- 2. Ahn HY, Lee MJ, Jung KY, Kim H–J, Jung EH, Chung CW, Kim KS, Jang JS, Park YJ, Lee JK, Cho SW. Selenium vs Control for Graves Ophthalmopathy in a Selenium–Sufficient Area: A Randomized Clinical Trial. JAMA Ophthalmol, 2025;143:287–294
- 3. Cho JY, Cho H-C, Ryu O-H, Kim H-J, Kim CG, Yun YR, Chung CH. Reference Standards for C-Peptide in Korean Population: A Korean Endocrine Hormone Reference Standard Data Center Study. Endocrinol Metab 2024;39:489-499.
- 4. Kim JT, Kim YM, Jung KY, Choi HS, Lee SY, Kim HJ. Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis. Korean J Int Med 2024;39:148-159.



# Curriculum Vitae

